Tuesday, January 17, 2017 11:08:11 AM
Learning as you go is called "hands-on experience." Experience is expensive and painful. Wisdom is less expensive with less risk of future self-inflicted pain.
I don't think Shore and/or Brar are out. Titan is too thin intellectually to just let them go. JMO. Agian, IMO - McNally has the knowledge to determine that Ximedica and/or Plexus are designing and building SPORT. Titan provided enough of the blueprint and direction about the design elements. I think Dr. Fowler (with the SAB) was the author of most of that. This new position brings "handling the reigns/management of product creation/development/production "direction" back in-house. If my guess is correct Brar and Shore have done thankless work to support Titan prior to McNally's arrival. McNally is putting wisdom, where hands-on experience has been. It's both mentor and executive, to get them to the next level in their careers, and SPORT in production. My point - SPORT is either done or very close to design freeze.
Titan needed to buy wisdom from outside sources to strengthen the breadth and depth of their internal executive resources. This position could easily be the No. 2 spot below the company president. No product - no sales. (IMO) Shore accepted responsibilities when Dr. Fowler left. Mr. Brar is IP and Strategy - which to me says IP R&D & protect IP. The VP position will report directly to McNally. This company has to have someone focused (at home office) on the engine/product while McNally is focused (and traveling) on the competition, finance, planning for sales, strategic partnerships or if they are approaching/approached - how to manage M&A.
This is a very good indicator to me of how McNally thinks, and what needs to be done to move SPORT to CE/FDA certification. I was wondering about a VP of Engineering. Check that box.
Also, a strong indication that funding has/is/will be addressed forthwith.
IMO.
Regards,
BK
Recent TMD News
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - TMD • PR Newswire (Canada) • 06/05/2023 05:46:00 PM
- IIROC Trade Resumption - TMD • PR Newswire (Canada) • 06/05/2023 05:37:00 PM
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - TMD • PR Newswire (Canada) • 06/05/2023 05:33:00 PM
- Canadian Investment Regulatory Organization Trading Halt - TMD • PR Newswire (Canada) • 06/05/2023 05:30:00 PM
- L'OCRCVM permet la reprise de la négociation - TMD • PR Newswire (Canada) • 05/26/2023 06:45:00 PM
- IIROC Trade Resumption - TMD • PR Newswire (Canada) • 05/26/2023 06:42:00 PM
- IIROC Trading Halt - TMD • PR Newswire (Canada) • 05/26/2023 06:16:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM